The next wave of amyloid-targeting projects approaches
Acumen is the latest player to take aim at amyloid, but competition is fierce.
Something seems to work in Alzheimer’s – and it’s more blood than brain
Grifols has announced intriguing results in a subgroup of patients in a large Alzheimer's disease study, Ambar, but the finding could also benefit other suppliers of…
Good luck to those who want to shame Celgene
Celgene is getting unwanted attention for the high price of Revlimid, but its pivotal position in multiple myeloma could help the company resist a shame campaign.
M&A comes back with a bang – or two – in medtech
The preponderance of large deals comes partly as a consequence of soaring market valuations; paradoxically, it is also a cause of them.
